Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

Quisette P. Janssen,Jacob L. van Dam,Marc G. Besselink,Marjolein Y.V. Homs,Geertjan van Tienhoven,Johanna W. Wilmink,Bas Groot Koerkamp

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

2021

Quisette P. Janssen
Jacob L. van Dam
Marc G. Besselink
Marjolein Y.V. Homs
Geertjan van Tienhoven
Johanna W. Wilmink
Bas Groot Koerkamp

TPS4171Background: Neoadjuvant therapy has several potential advantages over upfront surgery in patients with localized pancreatic cancer; more patients receive systemic treatment, fewer patients u...

Keywords:

Adjuvant
Chemoradiotherapy
FOLFIRINOX
borderline resectable
Medicine
Internal medicine
Oncology
Pancreatic cancer
Randomized controlled trial
Gemcitabine
Neoadjuvant therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations